Literature DB >> 21879078

Fabrication of doxorubicin functionalized gold nanorod probes for combined cancer imaging and drug delivery.

Tingting Wang1, Xuli Zhang, Ying Pan, Xiumin Miao, Zhongmin Su, Chungang Wang, Xiaomeng Li.   

Abstract

A novel strategy was utilized to develop a stable probe based on thiolated poly(ethylene glycol) (SH-PEG) and polyacrylic acid (PAA) functionalized gold nanorods (GNRs), following the attachment of an anti-cancer drug, doxorubicin (DOX), to obtain PAA-PEG-GNRs@DOX assemblies. Importantly, the obtained probe as a novel drug-delivery and fluorescent imaging agent for simultaneous imaging of and drug delivery to prostate cancer cells has also been demonstrated. In addition to designing PAA-PEG-GNRs that passively target tumor cells for cancer-fighting drug therapy, GNRs are also regarded as hyperthermia agents for photokilling cancer cells, so that the tumor would be attacked on two fronts simultaneously.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21879078     DOI: 10.1039/c1dt10565e

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  3 in total

1.  Gold nanoparticles induce nuclear damage in breast cancer cells, which is further amplified by hyperthermia.

Authors:  Mohamed Kodiha; Eliza Hutter; Sebastien Boridy; Michal Juhas; Dusica Maysinger; Ursula Stochaj
Journal:  Cell Mol Life Sci       Date:  2014-04-17       Impact factor: 9.261

2.  RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating α(v)β₃ expression.

Authors:  Wencai Xu; Teng Luo; Ping Li; Chuanqing Zhou; Daxiang Cui; Bo Pang; Qiushi Ren; Shen Fu
Journal:  Int J Nanomedicine       Date:  2012-02-27

Review 3.  Towards Effective Photothermal/Photodynamic Treatment Using Plasmonic Gold Nanoparticles.

Authors:  Alla Bucharskaya; Galina Maslyakova; Georgy Terentyuk; Alexander Yakunin; Yuri Avetisyan; Olga Bibikova; Elena Tuchina; Boris Khlebtsov; Nikolai Khlebtsov; Valery Tuchin
Journal:  Int J Mol Sci       Date:  2016-08-09       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.